CC BY-NC-ND 4.0 · J Knee Surg 2023; 36(09): 925-932
DOI: 10.1055/s-0042-1747945
Original Article

HTX-011 in Combination with Multimodal Analgesic Regimen Minimized Severe Pain and Opioid Use after Total Knee Arthroplasty in an Open-Label Study

Gwo-Chin Lee
1   Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
,
Richard Berkowitz
2   University Orthopedic and Joint Replacement Center, Tamarac, Florida
,
Scott Hacker
3   Grossmont Orthopedic Medical Group, La Mesa, California
,
Jia Hu
4   Heron Therapeutics, Inc., San Diego, California
,
Alan Rechter
5   Department of Orthopaedic Surgery, Orthopaedic Associates, LLP, Houston, Texas
› Author Affiliations
FundingThis study was funded by Heron Therapeutics. 4242 Campus Point Court Suite 200, San Diego, CA 92121. clinicaltrials.gov, NCT03974932. Editorial and submission assistance for this article was provided by Katie Luepke, PharmD, BCPS of Heron Therapeutics and Apothecom (funded by Heron Therapeutics)

Abstract

Total knee arthroplasty (TKA) can be associated with significant postoperative pain despite multimodal analgesic (MMA) protocols, and most patients require the use of opioids postoperatively. HTX-011 is a dual-acting local anesthetic containing bupivacaine and low-dose meloxicam in an extended-release polymer. In a prior randomized controlled trial (RCT), HTX-011 reduced pain and opioid use through 72 hours after TKA compared with bupivacaine hydrochloride. This open-label study (NCT03974932) evaluated the efficacy and safety of HTX-011 combined with an MMA regimen in patients undergoing TKA under spinal anesthesia. All patients received intraoperative HTX-011 (400 mg bupivacaine/12 mg meloxicam) in combination with an MMA regimen consisting of preoperative acetaminophen, celecoxib, and pregabalin and postoperative acetaminophen and celecoxib until discharge. Opioid rescue was allowed upon patient request for additional pain control. Pain scores, opioid consumption, discharge readiness, and adverse events were recorded. Fifty-one patients were treated. Compared with the prior RCT, HTX-011 with this MMA regimen further lowered pain scores and reduced opioid use. Mean patient-reported pain scores remained in the mild range, and 82% of patients or more did not experience severe pain at any individual time point through 72 hours after surgery. Mean total opioid consumption was low over 72 hours: 24.8 morphine milligram equivalents (1–2 tablets of oxycodone 10 mg/day). Approximately 60% of patients were ready for discharge by 12 hours, and 39% were discharged without an opioid prescription and did not call back for pain management. The treatment regimen was well tolerated, and no added risk was observed with the addition of MMA. HTX-011 with an MMA regimen reduced postoperative pain and opioid use following TKA.



Publication History

Received: 30 June 2021

Accepted: 25 February 2022

Article published online:
10 June 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Zlotnicki JP, Hamlin BR, Plakseychuk AY, Levison TJ, Rothenberger SD, Urish KL. Liposomal bupivacaine vs plain bupivacaine in periarticular injection for control of pain and early motion in total knee arthroplasty: a randomized, prospective study. J Arthroplasty 2018; 33 (08) 2460-2464
  • 2 Cook DJ, Kaskovich SW, Pirkle SC, Mica MAC, Shi LL, Lee MJ. Benchmarks of duration and magnitude of opioid consumption after total hip and knee arthroplasty: a database analysis of 69,368 patients. J Arthroplasty 2019; 34 (04) 638-644.e1
  • 3 Kehlet H, Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg 1993; 77 (05) 1048-1056
  • 4 Lamplot JD, Wagner ER, Manning DW. Multimodal pain management in total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty 2014; 29 (02) 329-334
  • 5 Hannon CP, Keating TC, Lange JK, Ricciardi BF, Waddell BS, Della Valle CJ. Anesthesia and analgesia practices in total joint arthroplasty: a survey of the American Association of Hip and Knee Surgeons membership. J Arthroplasty 2019; 34 (12) 2872-2877.e2
  • 6 Sreedharan Nair V, Ganeshan Radhamony N, Rajendra R, Mishra R. Effectiveness of intraoperative periarticular cocktail injection for pain control and knee motion recovery after total knee replacement. Arthroplast Today 2019; 5 (03) 320-324
  • 7 Ilfeld BM, Duke KB, Donohue MC. The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty. Anesth Analg 2010; 111 (06) 1552-1554
  • 8 Dysart SH, Barrington JW, Del Gaizo DJ, Sodhi N, Mont MA. Local infiltration analgesia with liposomal bupivacaine improves early outcomes after total knee arthroplasty: 24-hour data from the PILLAR study. J Arthroplasty 2019; 34 (05) 882-886.e1
  • 9 Schurr MJ, Gordon DB, Pellino TA, Scanlon TA. Continuous local anesthetic infusion for pain management after outpatient inguinal herniorrhaphy. Surgery 2004; 136 (04) 761-769
  • 10 Bates C, Laciak R, Southwick A, Bishoff J. Overprescription of postoperative narcotics: a look at postoperative pain medication delivery, consumption and disposal in urological practice. J Urol 2011; 185 (02) 551-555
  • 11 Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg 2017; 152 (11) 1066-1071
  • 12 Turnbull ZA, Sastow D, Giambrone GP, Tedore T. Anesthesia for the patient undergoing total knee replacement: current status and future prospects. Local Reg Anesth 2017; 10: 1-7
  • 13 Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy 2013; 33 (04) 383-391
  • 14 Oderda GM, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse events on outcomes in selected surgical patients. J Pain Palliat Care Pharmacother 2013; 27 (01) 62-70
  • 15 Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep 2017; 66 (10) 265-269
  • 16 Politzer CS, Kildow BJ, Goltz DE, Green CL, Bolognesi MP, Seyler TM. Trends in opioid utilization before and after total knee arthroplasty. J Arthroplasty 2018; 33 (7S): S147-S153, 153.e1
  • 17 Ottoboni T, Quart B, Pawasauskas J, Dasta JF, Pollak RA, Viscusi ER. Response to the letter to the editor by Hafer and Johnson concerning ‘Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain’. Reg Anesth Pain Med 2020; 45 (12) 1031-1032
  • 18 Ottoboni T, Gelder MS, O'Boyle E. Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. J Exp Pharmacol 2014; 6: 15-21
  • 19 Lachiewicz PF, Lee GC, Pollak RA, Leiman DG, Hu J, Sah AP. HTX-011 reduced pain and opioid use after primary total knee arthroplasty: results of a randomized phase 2b trial. J Arthroplasty 2020; 35 (10) 2843-2851
  • 20 Mont MA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local infiltration analgesia with liposomal bupivacaine improves pain scores and reduces opioid use after total knee arthroplasty: results of a randomized controlled trial. J Arthroplasty 2018; 33 (01) 90-96
  • 21 Themistoklis T, Theodosia V, Konstantinos K, Georgios DI. Perioperative blood management strategies for patients undergoing total knee replacement: where do we stand now?. World J Orthop 2017; 8 (06) 441-454
  • 22 Rothman M, Vallow S, Damaraju CV, Hewitt DJ. Using the patient global assessment of the method of pain control to assess new analgesic modalities in clinical trials. Curr Med Res Opin 2009; 25 (06) 1433-1443
  • 23 Chung F. Discharge criteria–a new trend. Can J Anaesth 1995; 42 (11) 1056-1058
  • 24 Chung F, Chan VW, Ong D. A post-anesthetic discharge scoring system for home readiness after ambulatory surgery. J Clin Anesth 1995; 7 (06) 500-506
  • 25 Zhang Y, Mi F, Zhao H, Xie D, Shi X. Effect of morphine added to multimodal cocktail on infiltration analgesia in total knee arthroplasty: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019; 98 (41) e17503
  • 26 Zhao B, Ma X, Zhang J, Ma J, Cao Q. The efficacy of local liposomal bupivacaine infiltration on pain and recovery after total joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019; 98 (03) e14092
  • 27 Seo SS, Kim OG, Seo JH, Kim DH, Kim YG, Park BY. Comparison of the effect of continuous femoral nerve block and adductor canal block after primary total knee arthroplasty. Clin Orthop Surg 2017; 9 (03) 303-309
  • 28 Li JW, Ma YS, Xiao LK. Postoperative pain management in total knee arthroplasty. Orthop Surg 2019; 11 (05) 755-761
  • 29 Gabriel RA, Swisher MW, Sztain JF, Furnish TJ, Ilfeld BM, Said ET. State of the art opioid-sparing strategies for post-operative pain in adult surgical patients. Expert Opin Pharmacother 2019; 20 (08) 949-961
  • 30 Gerbershagen HJ, Aduckathil S, van Wijck AJ, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology 2013; 118 (04) 934-944
  • 31 Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res 2017; 10: 2287-2298
  • 32 Adelani MA, Barrack RL. Patient perceptions of the safety of outpatient total knee arthroplasty. J Arthroplasty 2019; 34 (03) 462-464
  • 33 Bicket MC, White E, Pronovost PJ, Wu CL, Yaster M, Alexander GC. Opioid oversupply after joint and spine surgery: a prospective cohort study. Anesth Analg 2019; 128 (02) 358-364
  • 34 Viscusi E, Gimbel JS, Pollack RA, Hu J, Lee GC. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase III results from the randomized EPOCH 1 study. Reg Anesth Pain Med 2019; 44: 700-706
  • 35 Viscusi E, Minkowitz H, Winkle P, Ramamoorthy S, Hu J, Singla N. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study. Hernia 2019; 23 (06) 1071-1080
  • 36 Edwards PK, Milles JL, Stambough JB, Barnes CL, Mears SC. Inpatient versus outpatient total knee arthroplasty. J Knee Surg 2019; 32 (08) 730-735
  • 37 Chou R, Gordon DB, de Leon-Casasola OA. et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016; 17 (02) 131-157